Sign in
Taking people in United StatesPhase 1

Fat tissue injection compared with steroid injection for shoulder osteoarthritis

Compares injected fat tissue with corticosteroid injection in people with shoulder osteoarthritis.

Key facts

Who runs it
Stanford University
Where
Stanford, United StatesSee the site
Trial code
Registry title
The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis
Status
Recruiting
Phase
Phase 1
People taking part
48 people, planned
Started
28 Jul 2022
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Micro Fragmented Adipose Tissue
  • Corticosteroid injection
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with osteoarthritis (joint wear) of the main shoulder joint. Other treatments did not help them. It compares an injection of their own processed fat tissue with a steroid injection.

Age
25 to 75 years
Sex
All sexes
Disease stage
Osteoarthritis of the glenohumeral (main shoulder) joint seen on X-ray. People with no or little osteoarthritis cannot join. People with severe, bone-on-bone osteoarthritis cannot join either.
Earlier treatment
Other treatment must have failed first: at least 6 weeks of physical therapy, plus anti-inflammatory medicines unless they could not be used. Bracing or injections may also have been tried. People cannot join if they had a cortisone, PRP or hyaluronic acid injection into the joint in the last 3 months. They also cannot join after a stem cell injection into this shoulder.

Main reasons for not taking part

  • Past joint replacement or cartilage regrowth surgery, or other shoulder surgery planned
  • Inflammatory or rheumatologic arthritis, immune-changing treatment, fibromyalgia, or widespread chronic pain or opioid use
  • HIV, hepatitis C, bone or other infection, poorly controlled diabetes (HgA1C >7.0) or uncontrolled hormone disorder
  • BMI >40, a bleeding disorder or blood thinners, a large complete rotator cuff tear
  • Pregnancy or planned pregnancy

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Age between 25 and 75 years-old
  • Diagnosis of pre-existing osteoarthritis of the glenohumeral joint
  • Working understanding of the English language and able to fully understand the procedure
  • Capable of providing informed consent
  • Able to complete online, in-person or phone surveys for the purposes of follow-up
  • Capable of understanding pre- and post-procedure care instructions
  • Ambulatory at baseline
  • Previous trial and failure of conservative therapy consisting of a minimum of 6 weeks of physical therapy and trial of anti-inflammatory medications if not contraindicated, with or without concomitant bracing and/or injections

Who cannot take part

  • Prior total or partial joint replacement surgery or surgery involving cartilage regeneration
  • Previous cortisone, PRP or Hyaluronic acid intra-articular injection within the last 3 months
  • Currently undergoing immunomodulatory therapy
  • previous stem cell injection into treatment joint
  • Patient scheduled to undergo any concomitant shoulder surgical procedures or other surgery which may affect outcomes
  • Chronic pain involving multiple body parts or opioid medication management
  • Concomitant massive(2 tendons with retraction), complete rotator cuff tendon tear
  • Co-morbidity with the rheumatologic condition, inflammatory arthritis
  • Uncontrolled endocrine disorder
  • Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1, -2) and/or hepatitis C (HCV), infection, and poorly controlled diabetes (HgA1C >7.0)
  • Age < 25 or > 75 years old
  • Radiographs demonstrating either no, little osteoarthritis, severe(bone on bone) osteoarthritis
  • BMI >40 or joint space not visible by ultrasound
  • Pregnancy or planned pregnancy
  • Coagulopathy or anticoagulant treatment
  • Diagnosis of fibromyalgia

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 25 and 75 years old?

Where in United States

  • Stanford UniversityStanford, United StatesContact: Jessica Nguyen, BSTaking people

About the trial

What the trial wants to find out

This is a non-surgical trial comparing the clinical and functional outcomes of patients with osteoarthritis treated with Intra-articular injection of Micro Fragmented Adipose Tissue versus conventional therapy of intra-articular injection of corticosteroid.

The 2 groups in the trial

  • MFAT (Micro Fragmented Adipose Tissue)Treatment being tested

    Intra-articular shoulder injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's shoulder.

    Treatment: Micro Fragmented Adipose Tissue

  • Conventional TherapyExisting treatment, for comparison

    Intra-articular injection of corticosteroid (Triamcinolone 40mg)

    Treatment: Corticosteroid injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis
Plain-language title
Fat tissue injection compared with steroid injection for shoulder osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT04929951, who can take part
Record updated
17 August 2026